FIELD OF THE INVENTION The present invention relates to the items characterized in the patent claims, namely metal chelates useful for magnet resonance imaging of thrombi and their use for imaging of thrombi in a mammalian body. More particularly, the invention relates to high-affinity, specific-binding glycoprotein llb/llla antagonists labeled with paramagnetic chelates for imaging of thrombi. BACKGROUND

1. Introduction

Myocardial infarction (Ml), stroke, transient ischemic attacks (TIA) and pulmonary embolism (PE) are major causes of morbidity and mortality worldwide. These life-threatening clinical events are mostly caused by thrombi, which can be located in different vessels spread all over the body and can be of different size and composition. The origin of stroke or TIA can for example be a thrombus in the left atrium (LA) of the heart or in one of the big arteries between heart and brain like the carotid artery. In case of PE a venous thrombosis, often situated in the lower legs, can be the cause.

In a growing thrombus the final common step of platelet aggregation is characterized by the binding of activated glycoprotein llb/llla (GPIIb/llla) to blood fibrinogen resulting in a crosslinking inside the platelets. Design and development of glycoprotein llb/llla inhibitors (Scarborough R.M., Gretler D.D., J. Med. Chem. 2000, 43, 3453-3473) has been of considerable interest in pharmacological research with respect to anti-platelet and anti- thrombotic activity.

However, health care professionals are in need not only for compounds that prevent thrombosis in an acute care setting, but also for a satisfactory method of imaging thrombi. More particularly, thrombus imaging is of great importance for clinical applications such as thrombolytic intervention, in which the identification of the thrombus formation sites is essential for monitoring of therapy effects.

Thus thrombus imaging helps avoiding unnecessary prophylactic applications and therewith hazardous anticoagulant treatments (e.g. severe bleedings due to the reduced coagulation capacity).

The patient population which may benefit from such a diagnostic procedure is huge. According to the "Heart disease and Stroke Statistics - 2010 Update" of the American Heart Association 17.6 million people suffered from coronary heart disease only in the USA. Every year an estimated 785,000 Americans will have a new coronary attack, and approximately 470,000 will have a recurrent attack. Every year about 795,000 patients experience a new or a recurrent stroke. About 610,000 of these are first attacks. Of all strokes, 87% are ischemic, most of them due to a thromboembolic cause (Lloyd-Jones, D. et al., Circulation, 2010, 121(7): p. e46-215). The incidence of transient ischemic attack (TIA) in the United States has been estimated to be approximately 200,000 to 500,000 per year, with a population prevalence of 2.3%, which translates into about 5 million people (Easton, J.D. et al., Stroke, 2009, 40(6): p. 2276-2293). Individuals who have a TIA have a 90-day risk of stroke of 3.0% to 17.3% and a 10-year stroke risk of 18.8 %. The combined 10-year stroke, myocardial infarction, or vascular death risk is even 42.8% (Clark, T.G., M.F.G. Murphy, and P.M. Rothwell, Journal of Neurology, Neurosurgery & Psychiatry, 2003. 74(5): p. 577-580).

Imaging is forefront in identifying thrombus. Currently, thrombus imaging relies on different modalities depending on the vascular territory. Carotid ultrasound is used to search for carotid thrombus, transesophageal echocardiography (TEE) searches for cardiac chamber clot, ultrasound searches for deep vein thrombosis, and CT has become the gold standard for PE detection.

2. Description of the Prior Art, Problem to be solved and its Solution

Despite the success of the above mentioned techniques, there is still a strong need for an imaging solution for thrombus detection and monitoring: first, there are certain vascular territories which are underserved. For instance, despite the best imaging efforts still 30% to 40% of ischemic strokes are "cryptogenic," that is, of indefinite cause, or in other words, the source of the thromboembolism is still unfortunately not identified (Guercini, F. et al., Journal of Thrombosis and Hemostasis, 2008. 6(4): p. 549-554). Underlying sources of cryptogenic stroke include atherosclerosis in the aortic arch or intracranial arteries. Plaque rupture in the arch or other major vessels, in particular, is believed to be a major source of cryptogenic strokes and is very difficult to detect with routine methods. Recent clinical trial data from transesophageal echocardiography (TEE) studies showed that the presence of thickened vessel wall in the aortic arch was not predictive of ischemic stroke, although ulcerated aortic arch plaques were associated with cryptogenic stroke. A thrombus-targeted specific imaging approach has a great potential to identify clots in the presence of atherosclerotic plaques.

Moreover, there is still a strong need for an approach wherein a single modality is used to identify thrombus throughout the body. For instance, in a TIA or stroke follow-up, currently multiple examinations are required to search for the source of the embolus (Ciesienski, K.L. and P. Caravan, Curr Cardiovasc Imaging Rep., 2010. 4(1 ): p. 77-84). The therapeutic application of glycoprotein llb/llla inhibitors (Scarborough R.M., Gretler D.D., J. Med. Chem. 2000, 43, 3453-3473) has been of considerable interest in the past. Meanwhile three glycoprotein llb/llla antagonists are commercially available: a recombinant antibody (Abciximab), a cyclic heptapeptide (Eptifibatid) and a synthetic, non-peptide inhibitor (Tirofiban). Tirofiban (brand name AGGRASTAT ^® ) belongs to the class of sulfonamides and is the only synthetic, small molecule among the above mentioned pharmaceuticals. Duggan et. al., 1994, US 5,292,756 disclosed sulfonamide fibrinogen receptor antagonist as therapeutic agents for the prevention and treatment of diseases caused by thrombus formation.

Highly specific non-peptide glycoprotein llb/llla antagonists have been described in the prior art (Damiano et. al., Thrombosis Research 2001 104, 1 13-126; Hoekstra, W.J., et al., J. Med. Chem., 1999, 42, 5254-5265). These compounds have been known to be GPIIb/llla antagonist, effective as therapeutic agents with anti-platelet and anti-thrombotic activity (see W099/21832, WO97/41 102, WO95/08536, WO96/29309, W097/33869, WO9701/60813, US 6,515,130).

So far, there are only a few publications reporting on glycoprotein llb/llla specific contrast agents for thrombus imaging. US 5,508,020 describes radiolabeled peptides, methods and kits for making such peptides to image sites in a mammalian body labeled with technetium- 99m via Tc-99m binding moieties. The SPECT tracer apticide (AcuTect ^® ) is an approach to fulfill the need of thrombus imaging. Apticide is a Tc-99m labeled peptide, which specifically binds to the GPIIb/llla receptor. Dean and Lister-James describe peptides that specifically bind to GPIIb/llla receptors on the surface of activated platelets (US 5,645,815; US 5,830,856 and US 6,028,056). The authors show the detection of deep vein thrombosis employing Apticide. However, the unspecific binding of the technetium labeled peptide and the low signal to noise ratio are the drawbacks of this method resulting in a low resolution of the thrombus imaging. US 2007/0189970 describes compounds capable of binding to glycoprotein llb/llla. The disclosed compounds are labeled with a positron emitting isotope or ¹¹ C. WO2013/023795 discloses ¹⁸ F labeled compounds for binding to GPIIb/llla receptors and their use as diagnostic agent especially for imaging of thrombi by use of positron emission tomography (PET). In addition to nuclear medicine approaches for specific thrombus imaging, specific high relaxivity compounds for magnetic resonance imaging which are useful for the diagnosis of multiple pathologies, in particular cardiovascular, cancer- related and inflammatory pathologies, are described in US 2004/1 12839 A2 and US 2006/0239926 A1 . Klink et. al. (Arterioscler Thromb Vase Biol. 2010, 30(3): 403-410) describes a gadolinium-based contrast agent by coupling a cyclic peptide (cyclo[Cys-Arg- Gly-Asp-Cys]) to a small linker to Gd-DOTA (P975). The relaxivity per Gadolinium of P975 is 9 L/(mmol s) and the standard Gadolinium dose is used for the MRI detection of thrombosis (100 μηηοΙ Gd/kg bodyweight).

Uppal et. al., {Stroke 2010, 41 (6): 1271 -1277) describes a gadolinium-based contrast agent by coupling a fibrin targeting peptide (EP2104R). The relaxivity per Gadolinium of EP2104R is 10.6 L/(mmol s) (Overoye-Chan et.al., J.Am. Chem. Soc. 2008, 130, 6025-6039). For the MRI imaging of thrombosis a Gadolinium dose of 30 μηηοΙ Gd/kg bodyweigh (7.5 μηηοΙ EP2104R/kg bw) t is used.

Although the principle of associating a target specific binder (biovector) and a paramagnetic chelate has been known for quite some time, a specific MRI contrast agent has not yet been tested in clinical trials.

The targeting MRI approach does however present some difficulties. The main difficulty arises from the relatively low sensitivity of the MRI technique. Due to the intrinsically low sensitivity of MRI, high local concentrations of the contrast agent at the target site are required to generate detectable MR contrast. The detection limit of clinical available contrast agents is around 20 μηηοΙ Gd/L for in vitro and preclinical animal testing (Ciesienski et.al., Curr Cardiovasc Imaging Rep. 2010, 4(1 ), 77-84) and 125 μηιοΙ Gd/L for robust clinical application (Caravan et. al. Chem. Soc. Rev., 2006, 35, 512-523).

One approach to fulfill this requirement is to increase the relaxivity or the Gadolinium content per molecule.

In WO2004/1 12839 is stated on p. 9, 1 .10-15 that "the inventors went against the technical bias according to which it is preferable to use small molecules for specific medical imaging products. In fact, they were able to note that the steric hindrance of the HR chelate used does not impair the affinity of the specific product for its target. Despite a molecule weight of the order of 8 to 20 kD, the product effectively reaches its specific targeting site."

It now has been found, that the compound of the present invention have high relaxivities and high affinities for the GPIIbllla target despite the steric hindrance of the large Gadolinium chelate label.

The surprising technical effect of the compounds of the present invention is their potential for a significant dose reduction.

This surprising effect was confirmed by magnetic resonance imaging experiments. The used concentrations of the high affinity binders of the present invention were significantly lower (order of magnitudes) than the used clinical standard dose. The used standard dose of established contrast agents is 100 μηηοΙ Gd/kg bodyweight which leads to an average plasma concentration of about 590 μηηοΙ Gd/L 2 min post application (summary of product characteristics: Gadovist 1.0 mmol/ml solution for injection, Fachinformation Gadovist ^® 1 ,0 mmol/ml Injektionslosung). The used plasma concentration of the described compounds (0.8 μηηοΙ Gadolinium/L) was in the order of magnitudes lower that the approved market products.

The surprising effect of using extremely low doses was confirmed in an in vivo monkey experiment, (total dose: 4 μηηοΙ Gd/ kg bodyweight equals 0.5 μηηοΙ molecule/kg bw)

The dosage was in an at least 7.5-fold up to 25-fold lower compared to the most advanced preclinical thrombus specific imaging MRI experiments described by Klink et. al. (100 μηηοΙ Gd/kg bw, Arterioscler Thromb Vase Biol. 2010, 30(3): 403-410) and Uppal et. al. (30 μηιοΙ Gd/kg/bw, Siro/ e 2010, 41 (6): 1271 -1277). SUMMARY

The present invention is directed to compounds that bind to glycoprotein llb/llla and can be used for diagnostic imaging, in particular magnetic resonance imaging of thrombi. The disclosed compounds enable the binding to glycoprotein llb/llla receptor combined with an adequate imaging sensitivity.

DESCRIPTION of the INVENTION

In accordance with a first aspect, the present invention covers compounds of general formula (I) :

(I) . in which :

X represents a group selected from:

Y in which groups : Y represents

in which groups :

R ¹ represents Hydrogen, Methyl, Ethyl, Propyl or iso-Propyl ; represents Hydrogen, Methyl, Ethyl, Propyl or iso-Propyl ;

R ³ represents Hydrogen, Methyl, Ethyl, Propyl or iso-Propyl ; G represents a :

group ; in which :

R ⁴ represents Hydrogen, Methyl, Ethyl, Propyl, iso-Propyl or Benzyl represents Hydrogen, Methyl, Ethyl or Propyl ; represents Hydrogen, Methyl, Ethyl, Propyl, iso-Propyl or Benzyl

M represents Gadolinium ; m represents 1 or 2 ; n represents an integer of 2, 3, 4, 5 or 6 ; q represents 0 or 1 ; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

The compounds of this invention may contain one or more asymmetric centre, depending upon the location and nature of the various substituents desired. Asymmetric carbon atoms may be present in the (R) or (S) configuration, resulting in racemic mixtures in the case of a single asymmetric centre, and diastereomeric mixtures in the case of multiple asymmetric centres. In certain instances, asymmetry may also be present due to restricted rotation about a given bond, for example, the central bond adjoining two substituted aromatic rings of the specified compounds.

Preferred compounds are those which produce the more desirable biological activity. Separated, pure or partially purified isomers and stereoisomers or racemic or diastereomeric mixtures of the compounds of this invention are also included within the scope of the present invention. The purification and the separation of such materials can be accomplished by standard techniques known in the art.

The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example, by the formation of diastereoisomeric salts using an optically active acid or base or formation of covalent diastereomers. Examples of appropriate acids are tartaric, diacetyltartaric, ditoluoyltartaric and camphorsulfonic acid. Mixtures of diastereoisomers can be separated into their individual diastereomers on the basis of their physical and/or chemical differences by methods known in the art, for example, by chromatography or fractional crystallisation. The optically active bases or acids are then liberated from the separated diastereomeric salts. A different process for separation of optical isomers involves the use of chiral chromatography (e.g., chiral HPLC columns), with or without conventional derivatisation, optimally chosen to maximise the separation of the enantiomers. Suitable chiral HPLC columns are manufactured by Daicel, e.g., Chiracel OD and Chiracel OJ among many others, all routinely selectable. Enzymatic separations, with or without derivatisation, are also useful. The optically active compounds of this invention can likewise be obtained by chiral syntheses utilizing optically active starting materials.

In order to limit different types of isomers from each other reference is made to lUPAC Rules Section E (Pure Appl Chem 45, 1 1 -30, 1976).

The present invention includes all possible stereoisomers of the compounds of the present invention as single stereoisomers, or as any mixture of said stereoisomers, e.g. R- or S- isomers, or E- or Z-isomers, in any ratio. Isolation of a single stereoisomer, e.g. a single enantiomer or a single diastereomer, of a compound of the present invention may be achieved by any suitable state of the art method, such as chromatography, especially chiral chromatography, for example.

Further, the compounds of the present invention can exist as N-oxides, which are defined in that at least one nitrogen of the compounds of the present invention is oxidised. The present invention includes all such possible N-oxides. The present invention also relates to useful forms of the compounds as disclosed herein, such as metabolites, hydrates, solvates, prodrugs, salts, in particular pharmaceutically acceptable salts, and co-precipitates. The compounds of the present invention can exist as a hydrate, or as a solvate, wherein the compounds of the present invention contain polar solvents, in particular water, methanol or ethanol for example as structural element of the crystal lattice of the compounds. The amount of polar solvents, in particular water, may exist in a stoichiometric or non- stoichiometric ratio. In the case of stoichiometric solvates, e.g. a hydrate, hemi-, (semi-), mono-, sesqui-, di-, tri-, tetra-, penta- etc. solvates or hydrates, respectively, are possible. The present invention includes all such hydrates or solvates.

Further, the compounds of the present invention can exist in the form of a salt. Said salt may be any salt, either an organic or inorganic addition salt, particularly any pharmaceutically acceptable organic or inorganic addition salt, customarily used in pharmacy.

The term "pharmaceutically acceptable salt" refers to a relatively non-toxic, inorganic or organic acid addition salt of a compound of the present invention. For example, see S. M. Berge, et al. "Pharmaceutical Salts," J. Pharm. Sci. 1977, 66, 1 -19. The production of especially neutral salts is described in US 5,560,903.

A suitable pharmaceutically acceptable salt of the compounds of the present invention may be, for example, an acid-addition salt of a compound of the present invention bearing a nitrogen atom, in a chain or in a ring, for example, which is sufficiently basic, such as an acid-addition salt with an inorganic acid, such as hydrochloric, hydrobromic, hydroiodic, sulfuric, bisulfuric, phosphoric, or nitric acid, for example, or with an organic acid, such as formic, acetic, acetoacetic, pyruvic, trifluoroacetic, propionic, butyric, hexanoic, heptanoic, undecanoic, lauric, benzoic, salicylic, 2-(4-hydroxybenzoyl)-benzoic, camphoric, cinnamic, cyclopentanepropionic, digluconic, 3-hydroxy-2-naphthoic, nicotinic, pamoic, pectinic, persulfuric, 3-phenylpropionic, picric, pivalic, 2-hydroxyethanesulfonate, itaconic, sulfamic, trifluoromethanesulfonic, dodecylsulfuric, ethansulfonic, benzenesulfonic, para- toluenesulfonic, methansulfonic, 2-naphthalenesulfonic, naphthalinedisulfonic, camphorsulfonic acid, citric, tartaric, stearic, lactic, oxalic, malonic, succinic, malic, adipic, alginic, maleic, fumaric, D-gluconic, mandelic, ascorbic, glucoheptanoic, glycerophosphoric, aspartic, sulfosalicylic, hemisulfuric, or thiocyanic acid, for example.

Further, another suitably pharmaceutically acceptable salt of a compound of the present invention which is sufficiently acidic, is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically acceptable cation, for example a salt with N-methyl-glucamine, dimethyl-glucamine, ethyl-glucamine, lysine, dicyclohexylamine, 1 ,6-hexadiamine, ethanolamine, glucosamine, sarcosine, serinol, tris-hydroxy-methyl-aminomethane, aminopropandiol, sovak-base, 1 -amino-2,3,4-butantriol. Additionally, basic nitrogen containing groups may be quaternised with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides ; dialkyl sulfates like dimethyl, diethyl, and dibutyl sulfate ; and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and strearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others.

Those skilled in the art will further recognise that acid addition salts of the claimed compounds may be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods. Alternatively, alkali and alkaline earth metal salts of acidic compounds of the invention are prepared by reacting the compounds of the invention with the appropriate base via a variety of known methods.

The present invention includes all possible salts of the compounds of the present invention as single salts, or as any mixture of said salts, in any ratio.

In the present text, in particular in the Experimental Section, for the synthesis of intermediates and of examples of the present invention, when a compound is mentioned as a salt form with the corresponding base or acid, the exact stoichiometric composition of said salt form, as obtained by the respective preparation and/or purification process, is, in most cases, unknown.

Unless specified otherwise, suffixes to chemical names or structural formulae such as "hydrochloride", "trifluoroacetate", "sodium salt", or "x HCI", "x CF3COOH", "x Na+", for example, are to be understood as not a stoichiometric specification, but solely as a salt form.

This applies analogously to cases in which synthesis intermediates or example compounds or salts thereof have been obtained, by the preparation and/or purification processes described, as solvates, such as hydrates with (if defined) unknown stoichiometric composition.

The term "thrombus (thrombi)" describes all kinds of blood clots (venous and arterial thrombi). The term "thrombus (thrombi)" includes also any terms of phrases like "thrombotic deposits" and "thrombus formation sites". Thrombi usually arise as a result of the blood coagulation step in hemostasis or pathologically as the result of different causes like thrombotic disorders. In this investigation all platelet containing thrombi are included as well as circulating thrombi (embolus), which get stuck somewhere in the vascular tree.

In a second aspect, the present invention covers compounds of general formula (I), supra, in which :

X represents a group selected from:

in which groups : Y represents

in which groups :

R ¹ represents Hydrogen or Methyl ; R ² represents Hydrogen or Methyl ;

R ³ represents Hydrogen or, Methyl ; G represents a :

group ;

represents Hydrogen or Methyl

R ⁵ represents Hydrogen or Methyl ; represents Hydrogen or Methyl

M represents Gadolinium m represents 1 or 2 ; n represents an integer of 2, 3, 4, 5 or 6 ; q represents 0 or 1 ; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

In a third aspect, the present invention covers compounds of general formula (I), supra, in which :

X represents a group selected from: in which groups : Y represents a :

in which groups :

R ¹ represents Hydrogen ; R ² represents Hydrogen ; R ³ represents Hydrogen ; G represents a :

group ; in which :

R ⁴ represents Hydrogen or Methyl ;

R ⁵ represents Hydrogen or Methyl ;

R ⁶ represents Hydrogen ;

M represents Gadolinium ; m represents 1 ; n represents an integer of 2, 3 or 4; q represents 0 or 1 ;

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

In a fourth aspect, the present invention covers compounds of general formula (I), supra, in which : X represents a group selected from:

in which group :

Y represents a :

in which groups :

R ¹ represents Hydrogen ; represents Hydrogen ; represents Hydrogen ;

G represents a :

group ; in which :

R ⁴ represents Hydrogen or Methyl ; R ⁵ represents Hydrogen ; R ⁶ represents Hydrogen ; M represents Gadolinium ; m represents 1 ; n represents 3 or 4 ; q represents 0 or 1 ; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

In a fifth aspect, the present invention covers compounds of general formula (I), supra, which X represents a group selected from:

group , in which group :

Y represents a :

in which groups :

R ¹ represents Hydrogen ; R ² represents Hydrogen ; R ³ represents Hydrogen ; G represents a :

group ; in which :

R ⁴ represents Methyl ; R ⁵ represents Hydrogen ; R ⁶ represents Hydrogen ; M represents Gadolinium ; m represents 1 ; n represents 4 ; q represents 1 ; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

In a further aspect, the present invention covers compounds of general formula (I), supra, in which

X represents a group selected from: group

In a further aspect, the present invention covers compounds of general formula (I), supra, in which : represents a group selected from

group . In a further aspect, the present invention covers compounds of general formula (I), supra, in which :

X represents a :

In a further aspect, the present invention covers compounds of general formula (I), supra, which

X represents a :

In a further aspect, the present invention covers compounds of general formula (I), supra, which

Y represents a :

group.

In a further aspect, the present invention covers compounds of general formula (I), supra, which

Y represents a : group.

In a further aspect, the present invention covers compounds of general formula (I), supra, in which

Y represents a

group.

In a further aspect, the present invention covers compounds of general formula (I), supra, which

Y represents a :

group.

In a further aspect, the present invention covers compounds of general formula (I), supra, in which

R ¹ represents Hydrogen, Methyl, Ethyl, Propyl or iso-Propyl .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which

R ¹ represents Hydrogen or Methyl .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which

R ¹ represents Hydrogen .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which

R ¹ represents Methyl . In a further aspect, the present invention covers compounds of general formula (I), supra, in which

R ² represents Hydrogen, Methyl, Ethyl, Propyl or iso-Propyl .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which

R ² represents Hydrogen or Methyl .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which

R ² represents Hydrogen .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which

R ² represents Methyl .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which

R ³ represents Hydrogen, Methyl, Ethyl, Propyl or iso-Propyl .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which

R ³ represents Hydrogen or Methyl .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which

R ³ represents Hydrogen .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which R ³ represents Methyl .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which

G represents a :

group .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which

R ⁴ represents Hydrogen, Methyl, Ethyl, Propyl, iso-Propyl or Benzyl .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which

R ⁴ represents Hydrogen or Methyl .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which

R ⁴ represents Hydrogen .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which

R ⁴ represents Methyl .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which R ⁵ represents Hydrogen, Methyl, Ethyl or Propyl .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which

R ⁵ represents Hydrogen or Methyl .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which

R ⁵ represents Hydrogen . In a further aspect, the present invention covers compounds of general formula (I), supra, in which

R ⁵ represents Methyl . In a further aspect, the present invention covers compounds of general formula (I), supra, in which

R ⁶ represents Hydrogen, Methyl, Ethyl, Propyl, iso-Propyl or Benzyl . In a further aspect, the present invention covers compounds of general formula (I), supra, in which

R ⁶ represents Hydrogen or Methyl . In a further aspect, the present invention covers compounds of general formula (I), supra, in which

R ⁶ represents Hydrogen . In a further aspect, the present invention covers compounds of general formula (I), supra, in which R ⁶ represents Methyl .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which

M represents Gadolinium .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which m represents 1 or 2 .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which m represents 1 .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which m represents 2 .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which n represents an integer of 2, 3, 4, 5 or 6 .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which n represents an integer of 2, 3 or 4 .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which n represents 3 or 4 . In a further aspect, the present invention covers compounds of general formula (I), supra, in which n represents 3 .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which n represents 4 .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which

q represents 0 or 1 .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which q represents 0 .

In a further aspect, the present invention covers compounds of general formula (I), supra, in which

q represents 1 .

In a further aspect, the present invention covers compounds of general formula (I), selected from the group consisting of:

Octagadolinium 2,3-bis-{[2,3-bis({2,3-bis[(/V-{2-[4,7,10-tris(carboxylatome thyl)-1 ,4,7,10- tetraazacyclododecan-1 -yl]propanoyl}glycyl)amino]propanoyl}amino)propanoyl] amino}-/V-(4- {3-[(5-{(1 S)-2-carboxy-1 -[({(3R)-1 -[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino] ethyl}pyridin-3-yl)ethynyl]phenyl}butyl)propanamide .

Another aspect of the invention is the use of a compound of general formula (I) for diagnostic imaging.

Preferably, the use of a compound of the invention in the diagnosis is performed using magnetic resonance imaging (MRI). The invention also contains compounds of general formula (I) for the manufacture of diagnostic agents.

Another aspect of the invention is the use of the compounds of general formula (I) or mixtures thereof for the manufacture of diagnostic agents.

Another aspect of the invention is the use of the compounds of general formula (I) or mixtures thereof for the manufacture of diagnostic agents for imaging thrombi. A method of imaging body tissue in a patient, comprising the steps of administering to the patient an effective amount of one or more compounds of general formula (I) in a pharmeutically acceptable carrier, and subjecting the patient to NMR tomography. Such a method is described in US 5,560,903. For the manufacture of diagnostic agents, for example the adminstration to human or animal subjects, the compounds of general formula (I) or mixtures will conveniently be formulated together with pharmaceutical carriers or excipient. The contrast media of the invention may conveniently contain pharmaceutical formulation aids, for example stabilizers, antioxidants, pH adjusting agents, flavors, and the like. Production of the diagnostic media according to the invention is also performed in a way known in the art, see US 5,560,903. They may be formulated for parenteral or enteral administration or for direct administration into body cavities. For example, parenteral formulations contain a steril solution or suspension in a dosis of 0.0001 -5 mmol metal/kg body weight, especially 0.005-0.5 mmol metal/kg body weight of the compound of formula (I) according to this invention. Thus the media of the invention may be in conventional pharmaceutical formulations such as solutions, suspensions, dispersions, syrups, etc. in physiologically acceptable carrier media, preferably in water for injections. When the contrast medium is formulated for parenteral administration, it will be preferably isotonic or hypertonic and close to pH 7.4. In a further aspect, the invention is directed to a method of diagnosing a patient with a thromboembolic disease, such as myocardial infarction, pulmonary embolism, stroke and transient ischemic attacks. This method comprises a) administering to a human in need of such diagnosis a compound of the invention for detecting the compound in the human as described above and herein, and b) measuring the signal arising from the administration of the compound to the human, preferably by magnetic resonance imaging (MRI). In a further aspect, the invention is directed to a method of diagnosing a patient with a life threatening disease, such as aortic aneurism, chronic thromboembolic pulmonary hypertension (CETPH), arterial fibrillation and coronary thrombosis. This method comprises a) administering to a human in need of such diagnosis a compound of the invention for detecting the compound in the human as described above and herein, and b) measuring the signal from arising from the administration of the compound to the human, preferably by magnetic resonance imaging (MRI).

In a further aspect, the invention is directed to a method of diagnosing and health monitoring of cardiovascular risk patients. This method comprises a) administering to a human in need of such diagnosis a compound of the invention for detecting the compound in the human as described above and herein, and b) measuring the signal arising from the administration of the compound to the human, preferably by magnetic resonance imaging (MRI).

GENERAL SYNTHESIS

The compounds according to the invention can be prepared according to the following schemes 1 and 2.

The schemes and procedures described below illustrate synthetic routes to the compounds of general formula (I) of the invention and are not intended to be limiting. It is obvious to the person skilled in the art that the order of transformations as exemplified in the Schemes can be modified in various ways. The order of transformations exemplified in the Schemes is therefore not intended to be limiting. Appropriate protecting groups and their introduction and cleavage are well-known to the person skilled in the art (see for example T.W. Greene and P.G.M. Wuts in Protective Groups in Organic Synthesis, 3 ^rd edition, Wiley 1999). Specific examples are described in the subsequent paragraphs.

The term "amine-protecting group" as employed herein by itself or as part of another group is known or obvious to someone skilled in the art, which is chosen from but not limited to a class of protecting groups namely carbamates, amides, imides, N-alkyl amines, N-aryl amines, imines, enamines, boranes, N-P protecting groups, N-sulfenyl, N-sulfonyl and N- silyl, and which is chosen from but not limited to those described in the textbook Greene and Wuts, Protecting groups in Organic Synthesis, third edition, page 494-653, included herewith by reference. The "amine-protecting group" is preferably carbobenzyloxy (Cbz), p- methoxybenzyl carbonyl (Moz or MeOZ), ie f-butyloxycarbonyl (BOC), 9- fluorenylmethyloxycarbonyl (FMOC), benzyl (Bn), p-methoxybenzyl (PMB), 3,4- dimethoxybenzyl (DMPM), p-methoxyphenyl (PMP), triphenylmethyl (Trityl), methoxyphenyl diphenylmethyl (MMT) or the protected amino group is a 1 ,3-dioxo-1 ,3-dihydro-2H-isoindol-2- yl (phthalimido) or an azido group. The term "carboxyl-protecting group" as employed herein by itself or as part of another group is known or obvious to someone skilled in the art, which is chosen from but not limited to a class of protecting groups namely esters, amides and hydrazides, and which is chosen from but not limited to those described in the textbook Greene and Wuts, Protecting groups in Organic Synthesis, third edition, page 369-453, included herewith by reference. The "carboxyl-protecting group" is preferably methyl, ethyl, propyl, butyl, ie f-butyl, allyl, benzyl, 4- methoxybenzyl or 4-methoxyphenyl.

In general the synthesis of the GP llbllla binder moiety is documented in the literature: 1 ) J. Med. Chem. 1999, 42, 5254 - 5265

2) Organic Progress Research & Development 2003, 7, 866 - 872

3) WO 2013/023795

A stereoselective synthetic route is described in detail in the experimental part. The principal path to the pyridinium bromide A is exemplified in Scheme 1 :

Scheme 1

PG: protecting group

Palladium catalyzed Sonogashira reaction of the bromide A with an alkyne connected to the metal complex delivers the compounds of the general formula (I) as shown in scheme 2. Preferrably the final coupling reaction is perfomed in a partially aqueous solvent under use of water soluble palladium complexes like {palladium[2-(dimethylaminomethyl)phenyl][1 ,3,5- triaza-7-phosphaadamantane]chloride (Organometallics 2006, 25, 5768 - 5773) or trisodium 3,3',3"-phosphanetriyltris(4,6-dimethylbenzenesulfonate) as palladium ligand (Eur. J. Org. Chem. 2010, 3678 - 3683). Synthesis of the gadolinium containing unit bridged to alkyne functionality by a tetrameric or octameric amid framework was accomplished by peptide coupling technologies known to the expert in the field and is described in detail in the ex erimental part.

Scheme 2 Isolation and purification of the desired metal complex conjugates of the general formula (I) can be achieved by conventional chromatographic methods like preparative HPLC or size exclusion chromatography in case of poly Gadolinium complexes in combination with ultrafiltration methods.

DESCRIPTION OF THE FIGURES Figure 1 :

Affinity assay: In the first step human GPIIb/llla purified from human platelets was immobilized on a 96-well solid plate. After 48 hours the plates were washed and the unspecific binding sites were blocked with Roti ^® -Block. 2. In the next step, the plates were simultaneously incubated with a tritium labeled known GPIIb/llla binder ( ³ H) mixed with increasing concentrations of the novel compounds (inhibitor). The higher the affinity of the inhibitor, the lower the bound fraction of the tritiated known GPIIb/llla binder ( ³ H) was. The fraction of tritiated compound ( ³ H), which is not displaced by inhibitor, was measured in a microplate scintillation counter.

Figure 2:

Magnetic resonance imaging of in vitro platelet-rich thrombi and incubation solution (example 1 ) using a 3D turbo spin echo sequence (1 .5 T, Siemens Avanto, small extremity coil, TR 1050ms, TE 9.1 ms, 0.5x0.5x0.6 mm ³ ). In Figure 2a an in vitro control thrombus without the addition of a contrast agent is shown. The signal intensity of the control thrombus is slightly higher than the surrounding medium but clearly lower than the signal of the in vitro thrombus which was incubated with Example 1 as depicted in figure 2b. In figure 2c the incubation solution with a final concentration of 10 μηηοΙ substance/L of example 1 in human plasma is represented. The signal intensity is higher than the surrounding plasma solutions in the in vitro platelet-rich thrombi 2a and 2b.

The in vitro thrombus in figure 2b is incubated with the solution which is depicted in figure 2c. After 20 min incubation period the thrombi was washed three times with plasma solution. The signal intensity of the incubated in vitro thrombus in figure 2b shows a clearly higher signal than the control thrombi in figure 2a.

Figure 3:

Magnetic resonance imaging of in vitro platelet-rich thrombi and incubation solution (Example 1 ) using a 3D turbo spin echo sequence (1 .5 T, Siemens Avanto, small extremity coil, TR 1050ms, TE 9.1 ms, 0.5x0.5x0.6 mm ³ ). In Figure 3a an in vitro control thrombus without the addition of a contrast agent is shown. The signal intensity of the control thrombus is slightly higher than the surrounding medium but clearly lower than the signal of the in vitro thrombus which was incubated with Example 1 as depicted in figure 3b. In figure 3c the incubation solution with a final concentration of 0.1 μηηοΙ substance/L (0.8 μηηοΙ Gd//L) of example 1 in human plasma is represented. The signal intensity is comparable to the surrounding plasma solutions in the in vitro platelet-rich thrombi 3a and 3b. The in vitro thrombus in figure 3b is incubated with the solution which is depicted in figure 3c. After 20 min incubation period the thrombi was washed three times with plasma solution. The signal intensity of the incubated in vitro thrombus in figure 3b shows a clearly higher signal than the control thrombi in figure 3a. EXPERIMENTAL PART

Abbreviations Abbreviations

MTB methyl ie f-butyl ether

m multiplet

mc centred multiplet

NH4CI ammonium chloride

NMR nuclear magnetic resonance spectroscopy : chemical shifts (δ) are

given in ppm.

q quadruplets (quartet)

quin quintet

n (where i=1 , 2) relaxivities in L mmol ^"1 s ^"1

Rt retention time

RT room temperature

s singlet

Ri (where i=1 , 2) relaxation rates (1/Ti,2)

Ri(o) relaxation rate of the respective solvent

Tl,2 relaxation time

t triplet

TBAF tetrabutylammonium fluoride

TEE transesophageal Echocardiography

THF tetrahydrofuran

THP tetrahydropyran

TIA transient ischemic attack

UPLC ultra performance liquid chromatography

Materials and Instrumentation

The chemicals used for the synthetic work were of reagent grade quality and were used as obtained.

¹ H-NMR spectra were measured in CDCI3, D ₂ 0 or DMSO-de, respectively (294 K, Bruker DRX Avance 400 MHz NMR spectrometer (β ₀ = 9.40 T), resonance frequencies: 400.20 MHz for ¹ H 300 MHz spectrometer for ¹ H. Chemical shifts are given in ppm relative to sodium (trimethylsilyl)propionate-d4 (D2O) or tetramethylsilane (DMSO-d6) as internal standards (δ = 0 ppm).

Examples were analyzed and characterized by the following HPLC based analytical methods to determine characteristic retention time and mass spectrum: Method 1: UPLC (ACN-HCOOH):

Instrument: Waters Acquity UPLC-MS SQD 3001; column: Acquity UPLC BEH C18 1.7 50x2.1mm; eluent A: water + 0.1% formic acid, eluent B: acetonitril; gradient: 0-1.6 min 1- 99% B, 1.6-2.0 min 99% B; flow 0.8 ml/min; temperature: 60 °C; injection: 2 μΙ; DAD scan: 210-400 nm; ELSD

Method 2: UPLC (ACN-HCOOH polar):

Instrument: Waters Acquity UPLC-MS SQD 3001; column: Acquity UPLC BEH C18 1.7 50x2.1mm; eluent A: water + 0.1% formic acid, eluent B: acetonitril; gradient: 0-1.7 min 1- 45% B, 1.7-2.0 min 45-99% B; flow 0.8 ml/min; temperature: 60 °C; injection: 2 μΙ; DAD scan: 210-400 nm; ELSD

Examples

Example 1

Octagadolinium 2,3-bis-{[2,3-bis({2,3-bis[(A/-{2-[4,7,10-tris(carboxylatome thyl)-1 ,4,7,10- tetraazacyclododecan-1 -yl]propanoyl}glycyl)amino]propanoyl}amino)propanoyl] amino}-/V-(4-{3-[(5-{(1 S)-2-carboxy-1 -[({(3 ?)-1 -[3-(piperidin-4-yl)propanoyl]piperidin-3- yl}carbonyl)amino] ethyl}pyridin-3-yl)ethynyl]phenyl}butyl)propanamide

Diisopropyl amine (9.2 mL, 65 mmol) was added at 0°C to a 3M solution of ethyl magnesium bromide in diethyl ether (10.9 mL, 32.7 mmol) and additional diethyl ether (20 mL). After one hour at 0°C ie f-butyl acetate (4.3 mL, 32.7 mmol) was added and stirring was continued for 30 minutes. 5-Bromopyridine-3-carbonitrile (2.0 g, 10.9 mmol) in diethyl ether (42 mL) was added at 0°C. After two hours at 0°C saturated aqueous ammonium chloride solution was added. Phases were separated and the aqueous phase was extracted with diethyl ether. The combined extracts were washed with brine and dried over sodium sulfate. The solution was concentrated under reduced pressure and the residue was purified by chromatography on silica gel (ethyl acetate in hexane, 0 to 60%) to yield 1 .12 g ie f-butyl 3-amino-3-(5- bromopyridin-3-yl)prop-2-enoate.

¹ H-NMR (400 MHz, DMSO-de): δ = 1 .44 (s, 9 H), 4.77 (s, 1 H), 7.15 (br., 2 H), 8.22 (t, 1 H), 8.75 (d, 1 H), 8.76 (d, 1 H) ppm. Example 1 b

Terf-butyl (3S -3-amino-3-(5 5romopyridin-3-yl)propanoate

To chloro(1 ,5-cyclooctadien)rhodium(l) dimer (39 mg, 80 μηιοΙ) and (Rj-(-)-1 -[(S)-2-di-fe/f.- butyl-phosphino)ferrocenyl]ethyldi-(4-trifluormethylphenyl)p hosphine (108 mg, 160 μηηοΙ) under an argon atmosphere was added 2,2,2-trifluoroethanol (5.8 mL) and the solution was stirred for 40 minutes. To ie/f-butyl 3-amino-3-(5-bromopyridin-3-yl)prop-2-enoate (1 .59 g 5.32 mmol) in degassed 2,2,2-trifluoroethanol (1 1 .6 mL) in a pressure vessel was added the rhodium catalyst solution and the solution was stirred for 22 hours at 50°C under hydrogen pressure of 1 1 bar. The solution was concentrated under reduced pressure and the residue was purified by chromatography on silica gel (ethyl acetate in hexane, 12 to 100 % followed by methanol in ethyl acetate 0 to 15%) to yield 1 .16 g of enantiomerically enriched fe/f-butyl (3S)-3-amino-3-[5-(benzyloxy)pyridin-3-yl]propanoate.

1H-NMR (300 MHz, CDCI ₃ ): δ = 1 .43 (s, 9 H), 2.59 (d, 2 H), 4.42 (t, 1 H), 7.92 (t, 1 H), 8.58 (d, 1 H), 8.53 (d, 1 H) ppm.

a = -17.6° (c = 1.0g /100mL, CHCI3).

Example 1c Terf-butyl 4-{3-[(3 ?)-3-{[(2,5-dioxopyrrolidin-1 -yl)oxy]carbonyl}piperidin

propyl}piperidine-1 -carboxylate

To (3R)-1 -{3-[1 -(ie f-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidine-3-carbo xylic acid (1 .91 g, 5.18 mmol, Bioorg. Med. Chem. 2005, 13, 4343-4352, Compound 10) in 1 ,2- dimethoxyethane (13.5 mL) was added /V-hydroxysuccinimide (0.60 g, 5.18 mmol) and 1 ,3- dicyclohexyl carbodiimide (1 .18 g, 5.7 mmol). The solution was stirred for 4 hours at room temperature while a precipitate formed. The mixture was then cooled to 0°C filtrated and the solid washed with diethyl ether. The filtrate and the diethyl ether wash were combined and concentrated to yield 2.61 g of raw ie f-butyl 4-{3-[(3R)-3-{[(2,5-dioxopyrrolidin-1 - yl)oxy]carbonyl}piperidin-1 -yl]-3-oxopropyl}piperidine-1 -carboxylate.

UPLC (ACN-HCOOH): Rt. = 1.13 min.

MS (ES ⁺ ): m/e = 466.31 (M + H) ⁺ .

Example 1 d

Terf-butyl 4-{3-[(3 ?)-3-({(1 S)-1 -[5-bromopyridin-3-yl]-3-ferf-butoxy-3-oxopropyl} carbamoyl)piperidin-1 -yl]-3-oxopropyl}piperidine-1 -carboxylate

To ie/f-butyl (3S 3-amino-3-(5-bromopyridin-3-yl)propanoate (1 .33 g, 4.42 mmol) in DMF (17 mL) was added ie/f-butyl 4-{3-[(3R)-3-{[(2,5-dioxopyrrolidin-1 -yl)oxy]carbonyl}piperidin-1 -yl]- 3-oxopropyl}piperidine-1 -carboxylate (2.54 g, 4.91 mmol) and triethylamine (1 .85 mL, 13.2 mmol) in dichloromethane (17 mL) at 0°C. After 3 hours the mixture was quenched by addition of saturated aqueous ammonium chloride solution, phases were separated and the aqueous phase was extracted with diethyl ether. Combined organic extracts were dried over sodium sulphate, concentrated under reduced pressure and the residue was purified by chromatography on silica gel (ethyl acetate in hexane, 12 to 100% followed by methanol in ethyl acetate 0 to 15%) to yield 2.1 g of ie/f-butyl 4-[3-((3R)-3-{[(7S)-1 -(5-bromopyridin-3-yl)- 3-tert-butoxy-3-oxopropyl]carbamoyl} piperidin-1 -yl)-3-oxopropyl] piperidine-1 -carboxylate. UPLC (ACN-HCOOH): Rt. = 1.35 min.

MS (ES ⁺ ): m/e = 651.4 / 653.4 (M + H) ⁺ . Example 1e

(3S)-3-(5-Bromopyridin-3-yl)-3-[({(3 ?)-1 -[3-(piperidin-4-yl)propanoyl]piperidi

carbonyl)amino]propanoic acid

Terf-butyl 4-[3-((3R)-3-{[(iS)-1 -(5-bromopyridin-3-yl)-3-tert-butoxy-3-oxopropyl]carbamoyl} piperidin-1 -yl)-3-oxopropyl] piperidine-1 -carboxylate (600 mg, 0.94 mmol) was dissolved in formic acid and heated to 100°C for 12 minutes. The solvent was destilled off in vacuum and the residue purified by preparative HPLC To yield 330 mg of (3S)- 3-(5-bromopyridin-3-yl)-3-[({(3R)-1 -[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}

carbonyl)amino] propanoic acid.

UPLC (ACN-HCOOH): Rt. = 0.57 min.

MS (ES ⁺ ): m/e = 495.2, 497.2 (M + H) ⁺ . Example 1f

2-[4-(3-Hydroxyphenyl)butyl]-1 H-isoindole-1 ,3(2H)-dione

3,5-Dibromophenol (6.0 g, 23.8 mmol), 2-(but-3-en-1 -yl)-1 H-isoindole-1 ,3(2H)-dione (9.8 g, 49 mmol), palladium(ll)acetate (53 mg, 0.24 mmol) and tris(2-methylphenyl)phosphane (145 mg, 0.48 mmol) were stirred in acetonitrile (125 mL) and triethylamine (6.6 mL) for 5 hours at 90°C. After stirring for 15 hours at room temperature and concentration a mixture of 2-[4-(3- bromo-5-hydroxyphenyl)but-3-en-1 -yl]-1 /-/-isoindole-1 ,3(2H)-dione and 2,2'-[(5-hydroxy- benzene-1 ,3-diyl)dibut-1 -ene-1 ,4-diyl]bis(1 /-/-isoindole-1 ,3(2/-/)-dione) was obtained, which could be separated by chromatography on silica gel (ethyl acetate in hexane, 0 to 30 %) to yield 3.47 g of the bromo intermediate. The 2-[4-(3-bromo-5-hydroxyphenyl)but-3-en-1 -yl]- 1 /-/-isoindole-1 ,3(2/-/)-dione was solved in methanol (230 mL), water (18 mL) and ethyl acetate (192 mL) and stirred under a hydrogen atmosphere for in the presence of palladium on charcoal (10%, 437 mg) at 40°C for 2.5 hours. The reaction mixture was filtered through a path of celite, concentrated under reduced pressure and the residue was purified by chromatography on silica gel (ethyl acetate in hexane, 0 to 60%) to yield 2.41 g of 2-[4-(3- hydroxyphenyl)butyl]-1 /-/-isoindole-1 ,3(2H)-dione.

¹ H-NMR (300 MHz, DMSO-de): δ = 1 .41 - 1 .67 (m, 4H), 2.47 (m, 2H), 3.58 (t, 2H), 6.47 - 6.65 (m, 3H), 6.96 - 7.10 (t, 1 H), 7.76 - 7.92 (m, 4H), 9.21 (s, 1 H) ppm.

Example 1 g

3-[4-(1 ,3-Dioxo-1 ,3-dihydro-2H-isoindol-2-yl)butyl]phenyl trifluoromethanesulfonate

To 2-[4-(3-hydroxyphenyl)butyl]-1 H-isoindole-1 ,3(2/-/)-dione (4.24 g, 14.4 mmol) in pyridine (30 mL) was added trifluoromethane sulfonic anhydride (3.2 mL, 18.7 mmol) at 0°C. The mixture was stirred for one hour at 0°C, a mixture of water and diethyl ether was added, the phases were separated and the aqueous phase was extracted with diethyl ether. Combined organic extracts were washed with 0.5 M hydrochloric acid, dried over sodium sulphate. The solution was concentrated under reduced pressure while toluene was added two times before the end of the distillation and the residue was purified by chromatography on silica gel (ethyl acetate in hexane, 0 to 70%) to yield 5.34 g of 3-[4-(1 ,3-dioxo-1 ,3-dihydro-2/-/-isoindol- 2-yl)butyl]phenyl trifluoromethanesulfonate.

¹ H-NMR (300 MHz, DMSO-de): δ = 1 .50 - 1 .69 (m, 4H), 2.68 (t, 2H), 3.55 - 3.67 (t, 2H), 7.22 - 7.38 (m, 3H), 7.46 (t, 1 H), 7.77 - 7.94 (m, 4H) ppm. Example 1 h

2-(4-{3-[(Trimethylsilyl)ethynyl]phenyl}butyl)-1 H-isoindole-1 ,3(2H)-dione

To 3-[4-(1 ,3-dioxo-1 ,3-dihydro-2/-/-isoindol-2-yl)butyl]phenyl trifluoromethanesulfonate (5.3 g, 12.5 mmol), dichloropalladium(ll)bis(triphenylphosphane) (440 mg, 0.63 mmol), copper iodide (120 mg, 0.63 mmol) and Λ/,/V-diisopropylethylamine (1 1 ml_, 63 mmol) in DMF (20 mL) was added ethynyl(trimethyl)silane (8.7 ml_, 63 mmol) in DMF (1 1 mL) over 1 1 hours at 50°C. The mixture was stirred for 25 hours at 50°C while the ethynyl(trimethyl)silane (4.4 mL, 32 mmol) addition in DMF (5.6 mL) was repeated after 18 hours. A mixture of water and diethyl ether was added, the phases were separated and the aqueous phase was extracted with diethyl ether. Combined organic extracts were washed with brine, dried over sodium sulphate, concentrated under reduced pressure and the residue was purified by chromatography on silica gel (ethyl acetate in hexane, 0 to 25%) to yield 3.86 g of 2-(4-{3- [(trimethylsilyl)ethynyl]phenyl}butyl)-1 H-isoindole-1 ,3(2/-/)-dione.

¹ H-NMR (400 MHz, DMSO-d ₆ ): δ = 0.22 (s, 19H), 1.48 - 1 .65 (m, 4H), 2.59 (t, 2H), 3.59 (t, 2H), 7.17 - 7.33 (m, 4H), 7.75 - 7.91 (m, 4H) ppm.

Example 1 i

4-{3-[(Trimethylsilyl)ethynyl]phenyl}butan-1 -amine

To 2-(4-{3-[(trimethylsilyl)ethynyl]phenyl}butyl)-1 H-isoindole-1 ,3(2H)-dione (3.86 g, 10.3 mmol) in THF (83 mL) was added methyl hydrazine (8.1 mL, 15.4 mmol) and the solution was stirred for 41 hours at 40°C while a precipitate formed. The reaction mixture was concentrated to a volume of 40 mL and filtered at 0°C. The solid was washed with a small amount of cold THF and the combined filtrates concentrated under reduced pressure while toluene was added two times before the end of the distillation to yield 2.63 g of 4-{3- [(trimethylsilyl)ethynyl]phenyl}butan-1 -amine.

¹ H-NMR (300 MHz, DMSO-d ₆ ): δ = 0.22 (s, 9H), 1.26 - 1 .41 (m, 2H), 1.47 - 1.64 (m, 2H), 2.52 - 2.62 (m, 4H), 7.10 - 7.33 (m, 4H) ppm.

Example 1j

W-(ie^Butoxycarbonyl)-3-[(ieri-butoxycarbonyl)amino]-yV-(4-{ 3-[(trimethylsilyl)- ethynyl]phenyl}butyl)alaninamide

4-{3-[(Trimethylsilyl)ethynyl]phenyl}butan-1 -amine (2.6 g, 9.7 mmol) in DMF (40 mL) was added to a freshly prepared solution of /V-(ie f-butoxycarbonyl)-3-[(ie f-butoxycarbonyl)- amino]alanine /V-cyclohexylcyclohexanamine (5.0 g, 10.2 mmol), Λ/,/V-diisopropylethylamine (8.2 mL, 48.7 mmol) and HATU (5.2 g, 13.6 mmol) in DMF (50 mL) at 0°C. After stirring for one hour the mixture was filtered cold, the filtrate condensed, while remaining traces of DMF were distilled in the presence of toluene, and purified by chromatography on amino phase silica gel (ethyl acetate in hexane, 0 to 40%) to yield 4.25 g of /V-(ie f-butoxycarbonyl)-3- [(ie f-butoxycarbonyl)amino]-/V-(4-{3-[(trimethylsilyl) ethynyl] phenyl}butyl)alaninamide.

1H-NMR (300 MHz, DMSO-d ₆ ): δ = 0.22 (s, 9H), 1.35 - 1.43 (m, 2H), 1.36 (s, 18H), 1.44 - 1 .60 (m, 2H), 2.92 - 3.21 (m, 4H), 3.93 (dd, 1 H), 6.62 (d, 1 H), 6.71 (t, 1 H), 7.15 - 7.34 (m, 4H), 7.80 (t, 1 H) ppm.

Example 1 k

3-Oxo-3-[(4-{3-[(trimethylsilyl)ethynyl]phenyl}butyl)amin o]propane-1 ,2-diaminium dichloride

/V-(ie f-butoxycarbonyl)-3-[(ie f-butoxycarbonyl)amino]-/V-(4-{3-[(trimethylsilyl)ethynyl] phenyl}butyl)alaninamide (4.28 g, 8.0 mmol) in DMF (18.5 mL) was added hydrochloric acid in dioxane (4M, 18 mL). The solution was divided into two pressure vessels, which were sealed and irradiated in a microwave reactor for 16 minutes at 80°C. The combined reaction solution was diluted with 1 ,4-dioxane (300 mL), condensed to a volume of 50 mL and again diluted with 1 ,4-dioxane (200 mL). The mixture was stirred while a precipitate formed which was collected by filtration to yield 1.77 g of 3-oxo-3-[(4-{3-[(trimethylsilyl)ethynyl]phenyl} butyl)amino]propane-1 ,2-diaminium dichloride.

¹ H-NMR (300 MHz, DMSO-de): δ = 0.22 (s, 9H), 1 .46 (quin, 2H), 1.61 (m, 2H), 2.58 (t, 2H), 3.02 - 3.14 (m, 1 H), 3.17 - 3.27 (m, 3H), 4.19 (t, 1 H), 7.15 - 7.38 (m, 4H), 8.58 (br., 6H), 8.82 (t, 1 H) ppm. Example 1 m

yV-(ieri-butoxycarbonyl)-3-[(ieri-butoxycarbonyl)amino]alany l-3-({yV-(ieri-butoxy- carbonyl)-3-[(ieri-butoxycarbonyl)amino]alanyl}amino)-yV-(4- {3-[(trimethylsilyl)ethynyl]- phenyl}butyl)alaninamide

3-Oxo-3-[(4-{3-[(trimethylsilyl)ethynyl]phenyl}butyl)amin o]propane-1 ,2-diaminium dichloride (1 .77 g, 4.38 mmol) in DMF (40 mL) and Λ/,/V-diisopropylethylamine (4.4 mL) was added to a freshly prepared solution of /V-(ie f-butoxycarbonyl)-3-[(ie f-butoxycarbonyl)amino]-alanine N- cyclohexyl cyclohexanamine (4.4 g, 9.19 mmol), Λ/,/V-diisopropylethylamine (14 mL) and HATU (4.66 g, 12.3 mmol) in DMF (50 mL) at 0°C. After stirring for 60 minutes the mixture was condensed and purified by chromatography on amino phase silica gel (ethyl acetate in hexane, 0 to 100%) to yield 3.37 g of /V-(ie/f-butoxycarbonyl)-3-[(ie/f-butoxy- carbonyl)amino]alanyl-3-({/V-(ie f-butoxycarbonyl)-3-[(ie f-butoxycarbonyl)amino]alanyl}- amino)-/V-(4-{3-[(trimethylsilyl)ethynyl]phenyl}butyl)alanin e amide.

¹ H-NMR (400 MHz, DMSO-de): δ = 0.23 (s, 9H), 1 .39 (s, 36H), 1 .46 (quin, 2H), 1.59 (quin, 2H), 2.58 (t, 2H), 3.08 - 3.38 (m, 6H), 3.91 - 4.09 (m, 2H), 4.19 - 4.36 (m, 1 H), 6.19 (br, 1 H), 6.31 (br, 1 H), 6.45 (br, 1 H), 7.14 - 7.32 (m, 4H), 7.45 - 7.69 (br, 2H) ppm. Example 1 n

3-({(3-{[2,3-Diammoniopropanoyl]amino}-1 -oxo-1 -[(4-{3-[(trimethylsilyl)ethynyl] phenyl}butyl)amino]propan-2-yl}amino)-3-oxopropane-1 ,2-diaminium tetrachloride

To /V-(ie f-butoxycarbonyl)-3-[(ie f-butoxycarbonyl)amino]alanyl-3-({/V-(ie f-butoxy carbonyl)- 3-[(fe/f-butoxycarbonyl)amino]alanyl}ami phenyl}butyl)- alaninamide (4.48 g, 4.46 mmol) in DMF (21 mL) was added hydrochloric acid in dioxane (4M, 33 mL) The reaction vessel was sealed and irradiated in a microwave reactor for 10 minutes at 80°C. After cooling to room temperature the reaction mixture was slowly added to 1 ,4-dioxane (360 mL) while stirring. The formed precipitate was collected by filtration to yield 2.78 g of 3-({(3-{[2,3-diammoniopropanoyl]amino}-1 -oxo-1 -[(4-{3-[(trimethylsilyl)ethynyl]- phenyl}butyl)amino]propan-2-yl}amino)-3-oxopropane-1 ,2-diaminium tetrachloride.

1H-NMR (400 MHz, DMSO-d ₆ ): δ = 0.22 (s, 9H), 1 .42 - 1 .48 (m, 2H), 1 .53 - 1 .58 (m , 2H), 2.53 - 2.62 (m, 2H), 3.07 - 3.1 1 (m, 2H), 3.50 (br, 6H), 4.26 (br., 1 H), 4.33 (br., 1 H), 4.39 - 4.53 (m, 1 H), 7.16 - 7.36 (m, 4H), 8.40 - 9.10 (m, 12H) ppm.

Example 1 o

2,3-bis-{[2,3-bis({2,3-bis[(ieri-butoxycarbonyl)amino]propan oyl}amino)propanoyl] amino}-yV-(4-{3-[(trimethylsilyl)ethynyl]phenyl}butyl)propan amide

3-({(3-{[2,3-Diammoniopropanoyl]amino}-1 -oxo-1 -[(4-{3-[(trimethylsilyl)ethyn phenyl}butyl)- amino]propan-2-yl}amino)-3-oxopropane-1 ,2-diaminium tetrachloride (1 .0 g, 1.39 mmol) in DMF (16 mL) and Λ/,/V-diisopropylethylamine (4.7 mL) was added to a freshly prepared solution of N-(ie f-butoxycarbonyl)-3-[(tert-butoxycarbonyl)amino]-alanine /V-cyclohexyl cyclohexanamine (3.1 g, 6.37 mmol) and HATU (2.95 g, 7.76 mmol) in DMF (16 mL) and Λ/,/V-diisopropylethylamine (4.7 mL) at 20°C. After stirring for one hour and storage for 18 hours at 6°C the cold mixture was filtrated and the precipitate was washed with DMF. The filtrate was condensed, codestilled with toluene and the residue purified by chromatography on amino phase silica gel (ethyl acetate in hexane, 0 to 100%) to yield 1.38 g of 2,3-bis-{[2,3- bis({2,3-bis[(ie f-butoxycarbonyl)amino]propanoyl}amino)propanoyl] amino}-/V-(4-{3-[(tri- methylsilyl)ethynyl]phenyl}butyl)propanamide.

¹ H-NMR (400 MHz, DMSO-d ₆ ): δ = 0.23 (s, 9H), 1 .39 (s, 36H), 1 .46 (quin, 2H), 1.59 (quin, 2H), 2.58 (t, 2H), 3.08 - 3.38 (m, 6H), 3.91 - 4.09 (m, 2H), 4.19 - 4.36 (m, 1 H), 6.19 (br, 1 H), 6.31 (br, 1 H), 6.45 (br, 1 H), 7.14 - 7.32 (m, 4H), 7.45 - 7.69 (br, 2H) ppm.

Example 1 p

2,3-Bis({2,3-bis[(2,3-diammoniopropanoyl)amino]propanoyl}ami no)-W-(4-{3-[(trimet silyl)ethynyl]phenyl}butyl)propanamide octachloride

To 2,3-bis-{[2,3-bis({2,3-bis[(ie f-butoxycarbonyl)amino]propanoyl}amino)propanoyl] amino}- /V-(4-{3-[(trimethylsilyl)ethynyl]phenyl}butyl)propan amide (1.15 g, 0.7 mmol) in DMF (7.8 mL) was added hydrochloric acid in dioxane (4M, 7.8 mL) The reaction vessel was sealed and irradiated in a microwave reactor for 10 minutes at 80°C. Additional hydrochloric acid in dioxane (4M, 4 mL) and DMF (6mL) was added to the turbid mixture and irradiation in a microwave reactor for 10 minutes at 80°C was repeated. After cooling to room temperature the solution was slowly added to 1 ,4-dioxane (100 mL) while stirring. The formed precipitate was collected by filtration to yield 810 mg of 2,3-bis({2,3-bis[(2,3-diammonio propanoyl)amino]propanoyl}amino)-/V-(4-{3-[(trimethylsilyl)e thynyl]phenyl}butyl)propanamide octachloride.

¹ H-NMR (400 MHz, DMSO-d ₆ ): δ = 0.22 (s, 9H), 1 .44 (br, 2H), 1 .55 (br , 2H), 2.53 - 2.62 (m, 2H), 3.08 (br, 2H), 3.30 - 3.78 (br. m, 21 H), 4.28 (br., 3H), 4.43 (br., 2H), 4.53 (br.,1 H), 4.64 (br., 1 H), 7.20 - 7.36 (m, 4H), 8.40 - 9.10 (br. m, 24H) ppm.

Example 1 q

Octagadolinium 2,3-bis-{[2,3-bis({2,3-bis[(yV-{2-[4,7,10-tris(carboxylatome thyl)-1 ,4,7,10- tetraazacyclododecan-1 -yl]propanoyl}glycyl)amino]propanoyl}amino)propanoyl] amino}-yV-(4-{3-[(trimethylsilyl)ethynyl]phenyl}butyl)propan amide

Gadolinium 2,2',2"-[10-(1 -{[2-(4-nitrophenoxy)-2-oxoethyl]amino}-1 -oxopropan-2-yl)-1 ,4,7,10- tetraazacyclododecane-1 ,4,7-triyl]triacetate (2.43 g, 3.2 mmol) was added as a solid to 2,3- bis-({2,3-bis[(2,3-diammoniopropanoyl)amino]propanoyl}amino) -/V-(4-{3-[(trimethylsilyl)- ethynyl]phenyl}butyl)propanamide octachloride (200 mg, 170 μηιοΙ) in DMSO (8.5 mL), DMF (9.0 mL) and pyridine (0.6 mL) at 60°C. The mixture was stirred for 6 days at 60°C while triethylamine was added (day 1 : 33μί, day 4: 153 μί, day 5: 120 μί) and diluted by additional DMF (8.0mL) and DMSO (12 mL) after day 4. Addition of gadolinium 2,2',2"-[10-(1 - {[2-(4-nitrophenoxy)-2-oxoethyl]amino}-1 -oxopropan-2-yl)-1 ,4,7,10-tetraazacyclo dodecane- 1 ,4,7-triyl]triacetate (1 .0 g, 1.3 mmol) was repeated after day 4. The mixture was condensed under vacuum, diluted with water adjusted to pH 7 by aqueous sodium hydroxide and low molecular weight components were separated via ultrafiltration (cellulose acetate membrane, lowest NMWL 5000 g/mol, Millipore). The retentate was collected to yield 0.69 g of partially desilylated octagadolinium 2,3-bis-{[2,3-bis({2,3-bis[(/V-{2-[4,7,10-tris(carboxylatome thyl)- 1 ,4,7,10-tetraazacyclododecan-1 -yl]propanoyl}glycyl)amino] propanoyl}amino)propanoyl]- amino}-/V-(4-{3-[(trimethylsilyl)ethynyl]phenyl}butyl)propan amide.

UPLC (ACN-HCOOH polar): Rt. = 0.81 min.

MS (ES-): m/e = 2870.0 (M - 2H) ^2" .

Example 1 r

Octagadolinium 2,3-bis-{[2,3-bis({2,3-bis[(yV-{2-[4,7,10-tris(carboxylatome thyl)-1 ,4,7,10- tetraazacyclododecan-1 -yl]propanoyl}glycyl)amino]propanoyl}amino)propanoyl] amino}-/V-(4-{3-[(5-{(1 S)-2-carboxy-1 -[({(3 ?)-1 -[3-(piperidin-4-yl)propanoyl]piperidin-3- yl}carbonyl)amino] ethyl}pyridin-3-yl)ethynyl]phenyl}butyl)propanamide

To a degased solution of (3S)-3-(5-bromopyridin-3-yl)-3-[({(3R)-1 -[3-(piperidin-4-yl) propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid (13 mg, 26 μηιοΙ), triethylamine (20 μί, 130 μηηοΙ), and tetramethyl ammoniumfluoride (1 .2 mg, 13 μηηοΙ) in water (0.3 mL) and acetonitrile (0.7 mL), was added 1 .4 mL of a red catalyst solution, prepared by heating palladium(ll)acetate (6.0 mg, 27 μηηοΙ) with trisodium 3,3',3"-phosphanetriyltris(4,6- dimethylbenzenesulfonate) (70 mg, 107 μηηοΙ) in water (7 mL) for 30 minutes to 80°C. Octagadolinium 2,3-bis-{[2,3-bis({2,3-bis[(/V-{2-[4,7,10-tris (carboxylatomethyl)-l ,4,7,10-tetra- azacyclododecan-1 -yl]propanoyl}glycyl)amino]propanoyl} amino)propanoyl] amino}-/V-(4-{3- [(trimethylsilyl)ethynyl]phenyl}butyl)propanamide (302 mg, 52 μηηοΙ) in degased water (20 mL) was added over 10 hours at 60°C. The mixture was heated at 60°C for additional 15 hours while addidion of the previously prepared palladium catalyst solution (0.7 mL) was repeated. After cooling to room the mixture was condensed and the residue was diluted with water (150 mL) and filtrated through a cellulose acetate membrane, lowest NMWL 10000 g/mol (Millipore). The filtrate was collected and Ultrafiltration was repeated through a cellulose acetate membrane, lowest NMWL 5000 g/mol (Millipore). The Retentate was condensed and purified by preparative HPLC (C18-YMC ODS AQ-10 μηη, acetonitrile in water + 0.1 % formic acid, 1 % to 25%) to yield 14.4 mg of the title compound after condensation.

UPLC (ACN-HCOOH polar): Rt. = 0.84 min.

MS (ES-): m/e = 3040.6 (M - 2H) ^2" .

Reference Compound

(3S)-3-[({(3/?)-1 -[3-(Piperidin-4-yl)prop

pyridin-3-yl}propanoic acid

(3S)-3-(6-Bromopyridin-3-yl)-3-{[(3R)-1 -(3-piperidin-4-yl-propanoyl)piperidine-3-carbonyl] amino}propanoic acid (1 .85 mg, 3.73 μηηοΙ) was dissolved in a mixture of DMF (500 μΙ_) and triethylamine (25 μΙ_). To this solution palladium on charcoal (20%) (6.45 mg) was added and the mixture was connected to a tritium manifold to tritiate over night with tritium gas. Afterwards the reaction mixture was 3 times cryostatically evaporated in the manifold. The obtained crude product was purified on a semi prep HPLC (Kromasil 100 C8 5 μηη (250x 4.6 mm), eluent: 35 mM ammonia/methanol, flow: 1 mL/min). The collected fraction contained 2061 MBq (S)-3-{5-3H-pyridin-3-yl}-3-{[(R)-1 -(3-piperidin-4-yl-propanoyl)piperidin-3- carbonyl]amino}propanoic acid (radiochemical yield: 12.6 %; radiochemical purity: 98%; specific activity: 7.81 Ci/mmol).

Example 2

Affinities of investigated compounds towards human GPIIb/llla receptors

The procedure of the used GPIIb/llla affinity assay is schematically demonstrated in figure 1. Purified human glycoprotein llb/llla (20 mM Tris-HCI, 0.1 M NaCI, 0.1 % Triton X-100, 1 mM CaC , 0.05% NalS , 50% Glycerol, pH 7.4) was purchased from Enzyme Research Laboratories Inc. (South Bend, IN). The GPIIb/llla receptor was diluted in phosphate-buffered saline (Dulbecco's Phosphate Buffered Saline (D-PBS (+)) with calcium and magnesium, GIBCO ^® , Invitrogen) with 0.01 % bovine serum albumin (albumin from bovine serum - lyophilized powder,≥96 %, Sigma). The GPIIb/llla receptor was immobilized 48 hours at least (100 μΙ_ per well, 48 to maximum 96 hours) on a 96-well solid plate (Immuno Plate MaxiSorp™, Nunc, Roskilde, Denmark) at 277 K to 280 K and at a concentration of 0.1 μg per well to 1 μg per well. As negative control one row of the plate (n=8) was incubated just with 2% bovine serum albumin (200 μΙ_ per well, albumin from bovine serum - lyophilized powder,≥96%, Sigma, diluted in D-PBS (+)). After washing three times with the wash buffer (230 μΙ_ per well, Dulbecco's Phosphate Buffered Saline (D-PBS (-)) contains no calcium or magnesium, GIBCO ^® , Invitrogen) residual exposed plastic and unspecific binding sites were blocked by incubating the plate with a special blocking solution (200 μΙ_ per well, Roti®-Block, Car Roth GmbH Co KG, Karlsruhe) containing 2% bovine serum albumin (Albumin from bovine serum - lyophilized powder, ≥96%, Sigma) 1 hour at room temperature.

After washing three times with the wash buffer 50 μΙ_ of tritiated reference compound (60 nM, ³ H-labeled compound) and 50 μΙ_ of novel compound (inhibitor) were simultaneously added to each well and incubated for 1 hour at room temperature. Several concentrations of each novel inhibitor (0.1 , 1 , 2, 5, 10, 20 50, 100, 200, 500, 1000, 2000, 5000, 10000 and 20000 nM) were investigated. At each concentration of inhibitor a fourfold determination was performed. The results for the examined inhibitors are summarized in table 1.

The maximum value of tritiated reference compound was determined without addition of inhibitor (n=8). To exclude unspecific binding of ³ H- reference compound wells without glycoprotein receptors were used as negative controls (n=12, identically treated just without GPIIb/llla receptors).

After one hour the plate was washed three times with phosphate-buffered saline (200 μΙ_ per well, Dulbecco's Phosphate Buffered Saline (D-PBS (+)), GIBCO ^® , Invitrogen). Following 140 μΙ_ of liquid scintillation cocktail (MicroScint™ 40 aqueous, Perkin Elmer) was added to each well. After 15 min at room temperature the plates were measured at the microplate scintillation counter (TopCount NXT v2.13, Perkin Elmer, Packard Instrument Company).

Figure 1 shows a schematic diagram of GPIIb/llla assay. In the first step human glycoprotein llb/llla, which is purified from human platelets, was immobilized on a 96-well solid plate. After 48 hours at least the plates were washed and the unspecific binding sites were blocked with Roti ^® -Block. 2. In the next step, the plates were simultaneously incubated with a tritium labeled reference compound and the novel small molecule compound (inhibitor). 3. The higher the affinity of the inhibitor, the smaller is the bound fraction of reference compound. The fraction of tritiated reference compound, which is not displaced by inhibitor, was measured at a microplate scintillation counter. The higher the affinity of the inhibitor, the smaller is the bound fraction of tritium-labeled reference compound. By means of this assay the affinities (IC50 values) could be determined. The studies described above indicate that compounds of formula (I) are useful as contrast agents for the imaging of thrombi. The results are summarized in table 1 .

Table 1 : Binding affinity of compounds towards human GPIIb/llla receptor.

Example 3

Binding of investigated compounds to human activated platelets

For each experiment fresh blood was taken from a volunteer using 10 mL citrate-tubes (Sarstedt S-Monovette 02.1067.001 , 10 mL, Citrate 3.13%). The 10 mL citrate- tubes were carefully inverted 10 times to mix blood and anticoagulant. The tubes were stored in an incubator at a temperature of 37°C until centrifugation (Heraeus miniTherm CTT with integrated rotation- and turning device, turning speed: 19 rotations per minute, Heraeus Instruments GmbH, Hanau/Germany).

For plasma preparation tube centrifugation was carried out for 15 minutes at 181 1 g at room temperature (Eppendorf, Centrifuge 581 OR). To produce platelet-rich plasma blood was centrifuged 15 minutes at 201 g at room temperature. The tubes were stood for 30 min at room temperature to get a better separation. The separated platelet-rich plasma was finally centrifuged for further 3 min at 453 g to remove the remaining erythrocytes. The platelet-rich plasma was activated using a final concentration of 5 μΜ Adenosindiphosphate (ADP, Sigma). The activated platelet-rich plasma was incubated 20 minutes and 3 min with different concentrations of gadolinium-labeled compound and subsequently was centrifuged 3 minutes at 1360 g. 20 μΙ_ of supernatant was taken to determine the concentration (n=3). The pellet was resuspended and washed two times with at least 750 μΙ_ plasma and subsequently was redispered in 750 μΙ_ plasma and 50 μΙ_ calciumchloride (50 μΙ_ 2%). The gadolinium concentration of supernatant and pellet was determined using an inductively coupled plasma mass spectrometry (ICP-MS Agilent 7500a).

The results for incubation concentrations of 10 μΜ, 1 μΜ and 0.1 μΜ of gadolinium-labeled compound are summarized in table 2. Table 2: Binding of compounds to human activated platelets.

Example 4

Magnetic resonance imaging

The MRI imaging experiments were done with platelet-rich plasma. The preparation of platelet-rich plasma using fresh blood is described in LK Jennings et. al. Blood 1986 1 , 173- 179 but modified with regard to centrifugation procedure. Briefly, fresh blood was taken from a volunteer using 10 mL citrate-tubes (Sarstedt S-Monovette 02.1067.001 , 10 mL, Citrate 3.13%). The 10 mL citrate-tubes were carefully inverted 10 times to mix blood and anticoagulant. The blood samples were centrifuged 15 minutes at 1 10 g at room temperature (Eppendorf, Centrifuge 581 OR). The tubes were stored for 30 min at room temperature to get a better separation. The separated plasma fraction was centrifuged 3 minutes at 240 g at room temperature to remove remaining erythrocytes. The erythrocyte pellet was eliminated. The platelets in the supernatant were activated using a final concentration of 5 μηΊθΙ/L Adenosindiphosphate (ADP, Sigma).

The activated platelet -rich plasma solution was incubated 20 minutes at 37°C with example 1 achieving a final concentration of Ι Ο μηηοΙ substance/L (Figure 2) and 0.1 μηηοΙ substance/L (Figure 3). After incubation the samples were centrifuged 3 minutes at 720 g. The supernatant was eliminated and the pellet was washed with 750 μί human plasma three times by repeated redispersing and subsequent centrifugation. In the last washing step Calciumchlorid (70 μί 2%) was added to human plasma to induce platelet aggregation. After 40 min the resulting in vitro platelet-rich thrombi were fixed in 2.0 mL tubes (2.0 mL Eppendorf microcentrifuge tubes) and magnetic resonance imaging in human plasma was performed at room temperature.

The images were performed using a clinical 1.5T system (Siemens Avanto) equipped with a small extremity coil. A Ti-weighted 3D turbo spin echo sequence (3D TSE) with a repetition time (TR) of 1050 ms and an echo-time of 9.1 ms and a turbo factor of 25 was used. The 3D block contains 18 slices each witch a slice thickens of 0.6mm. The spatial resolution of the 3D TSE sequence was 0.5x0.5x0.6 mm3 with an image matrix of 256x172x18 pixel. The number of signal averages was 16 with a resulting total acquisition time of 17 min and 41 seconds.

The magnetic resonance imaging results are depicted in Figure 2 and Figure 3.

In Figure 2a an in vitro control thrombus without the addition of a contrast agent is shown. The signal intensity of the control thrombus is slightly higher than the surrounding medium but clearly lower than the signal of the in vitro thrombus which was incubated with Example 1 as depicted in figure 2b. In figure 2c the incubation solution with a final concentration of 10 μηηοΙ substance/L of example 1 in human plasma is represented. The signal intensity is higher than the surrounding plasma solutions in the in vitro platelet-rich thrombi 2a and 2b. The in vitro thrombus in figure 2b is incubated with the solution which is depicted in figure 2c. After 20 min incubation period the thrombi was washed three times with plasma solution. The signal intensity of the incubated in vitro thrombus in figure 2b shows a clearly higher signal than the control thrombi in figure 2a.

In Figure 3a an in vitro control thrombus without the addition of a contrast agent is shown. The signal intensity of the control thrombus is slightly higher than the surrounding medium but clearly lower than the signal of the in vitro thrombus which was incubated with Example 1 as depicted in figure 3b. In figure 3c the incubation solution with a final concentration of 0.1 μηηοΙ substance/L (0.8 μηηοΙ Gd//L) of example 1 in human plasma is represented. The signal intensity is comparable to the surrounding plasma solutions in the in vitro platelet-rich thrombi 3a and 3b. The in vitro thrombus in figure 3b is incubated with the solution which is depicted in figure 3c. After 20 min incubation period the thrombi was washed three times with plasma solution. The signal intensity of the incubated in vitro thrombus in figure 3b shows a clearly higher signal than the control thrombi in figure 3a.

Example 5

Specific thrombus binding in Cynomolgus Monkey

The specific binding of the compound described in Example 1 was investigated in cynomolgus monkey (female 3,0 kg bodyweight).

The monkey was anesthetized with a mixture of Xylazin (Rompun®, Bayer Healthcare, Leverkusen, Germany), 0.12 mL/Kg and Ketamine (Ketavet®, Pfizer) 0.12 mL/Kg b.w. i.m.. While the investigation, small amounts of Xylazin/Ketamine (1 +1 ) have been injected i.m. if required. The left common carotid artery was exposed 10 min with iron-ill-chloride solution (10%). Following thrombus induction the monkey received 1 μηηοΙ Gadolinium/ kg bodyweight (equals 0.125 μηηοΙ molecule/kg bodyweight) i.v.. Afterwards, the right carotid artery was exposed 8 min with iron-ill-chloride solution (10%) and the monkey received a repeated dose of 1 μηηοΙ Gadolinium / kg bodyweight iv.

After the first two contrast media applications the right carotid artery was exposed surgically and a polyethylene-tube (INTRAMEDIC Polyethylene Tubing, Clay Adams, PE50), which was roughened previously by sandpaper (600 - CAMI Grit designation), was inserted into the vessel, advanced into the descending aorta and was left there for 30 minutes to allow for the development of a thrombus on the rough surface of the tube. The monkey received 1 μηηοΙ Gadolinium/ kg bodyweight (equals 0.125 μηηοΙ molecule/kg bodyweight) i.v. 30 min and 90 min post catheterization. 40 min after the last contrast media application the animal was sacrificed using Pentobarbital (Narcoren). The gadolinium concentrations in blood, thombus of the left and right carotis, right carotis, left carotis, jugular vein and aorta were determined using an inductively coupled plasma mass spectrometry (ICP-MS Agilent 7500a). The data are summarized in table 3.

Table 3: Inductively coupled plasma mass spectrometry data fot the Gadolinium determination in different tissues after repeated doses of Example 1 in Cynomolgus Monkey (40 min after last injection, 4 repeated doses of 1 μΜ Gadolinium/ kg bw, total dose 4 μΜ Gadolinium/ kg bw).